女性混合性尿失禁的尿道中段吊带术与A型肉毒毒素注射比较:MUSA随机临床试验
这项随机优效性试验在7个美国中心纳入150例经保守治疗无效的中重度混合性尿失禁女性,比较膀胱内注射A型肉毒毒素100U与尿道中段合成吊带术。6个月时两组UDI总分均改善且组间无显著差异(平均差18.1分,95%CI -4.6至40.7,P=0.12)。吊带术在压力性尿失禁评分改善上优于肉毒毒素注射(P<0.001),刺激性评分两组无显著差异。
要点
- 6个月UDI总分改善两组无显著差异,平均差18.1分(95%CI -4.6至40.7,P=0.12)。
- 吊带术UDI压力评分改善优于肉毒毒素注射(-45.2 vs -25.1,P<0.001)。
- 12个月内吊带组30.3%接受肉毒毒素注射,肉毒毒素组15.5%接受吊带术。
核心结论
- 在既往保守治疗无效的中重度混合性尿失禁女性中,A型肉毒毒素注射与尿道中段吊带术6个月UDI总分改善无显著差异。
- 这些发现可能有助于结合患者偏好与临床医生建议共同制定治疗决策。
研究设计与样本
- 随机优效性试验,在美国7个中心开展,入组时间为2020年7月至2022年9月,末次随访日期为2023年12月29日。
- 纳入年龄≥21岁、同时存在压力性和急迫性尿失禁且造成中度至重度困扰、保守治疗和口服药物无效的女性。
- 150例女性被随机分组,其中137例接受治疗、有基线后结局数据并纳入主要分析,平均(SD)年龄59.0(11.5)岁。
- 干预为膀胱内注射A型肉毒毒素100U(针对急迫性成分)与合成网片尿道中段吊带术(针对压力性成分)比较。
- 肉毒毒素组可在3至6个月接受追加注射;所有参与者在6至12个月可接受额外治疗,包括交叉至替代治疗。
主要发现
- 6个月时两组UDI总分均改善:肉毒毒素组-66.8分(95%CI -84.9至-48.8),吊带组-84.9分(95%CI -100.5至-69.3),平均差18.1分(95%CI -4.6至40.7),P=0.12。
- UDI压力评分改善吊带组优于肉毒毒素组:吊带组-45.2(95%CI -53.7至-36.8) vs 肉毒毒素组-25.1(95%CI -34.1至-16.1),P<0.001。
- UDI刺激性评分两组无显著差异:肉毒毒素组-32.9(95%CI -40.3至-25.6) vs 吊带组-27.4(95%CI -34.6至-20.3),P=0.27。
- 肉毒毒素组中,6个月和12个月时分别有12.7%和28.2%接受了第二次注射。
- 12个月时,吊带组30.3%接受了A型肉毒毒素注射,肉毒毒素组15.5%接受了吊带术;总体不良事件两组无差异。
临床怎么用
- 原文结论指出,这些发现可能有助于结合患者偏好与临床医生建议共同制定治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mixed urinary incontinence, which includes both stress and urgency urinary incontinence, adversely affects quality of life and can be difficult to manage. Studies comparing procedural-based treatments for mixed urinary incontinence are lacking. OBJECTIVE: To determine whether intradetrusor onabotulinumtoxinA is more effective than midurethral sling for the treatment of mixed urinary incontinence in females. DESIGN, SETTING, AND PARTICIPANTS: Randomized, superiority trial involving females (aged ≥21 years) with moderate to severe bother from both stress and urgency urinary incontinence who had unsuccessful conservative treatments and oral medications. The study was conducted at 7 US sites with enrollment between July 2020 and September 2022; the last date of follow-up was December 29, 2023. INTERVENTIONS: Intradetrusor injection of onabotulinumtoxinA, 100 U (treatment focused on the urgency component), vs surgical synthetic mesh midurethral sling (treatment focused on the stress component). Recipients of onabotulinumtoxinA could receive an additional injection between 3 and 6 months. All participants could receive additional treatment (including crossover to the alternative treatment) between 6 and 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was change at 6 months in mixed incontinence symptoms as measured by the Urogenital Distress Inventory (UDI) total score (0-300 points; higher scores indicate worse symptoms; minimal clinically important difference, 26.1). Secondary outcomes included stress and irritative UDI subscores. RESULTS: Among 150 females randomized, 137 were treated, had postbaseline outcome data, and were included in the primary analysis (mean [SD] age, 59.0 [11.5] years). Both groups demonstrated mean improvement in UDI total score at 6 months with no significant difference between groups (onabotulinumtoxinA: -66.8 points [95% CI, -84.9 to -48.8]; sling: -84.9 [95% CI, -100.5 to -69.3]; mean difference, 18.1 points [95% CI, -4.6 to 40.7]; P = .12). For secondary outcomes, greater UDI stress score improvement was seen with the sling (-45.2 [95% CI, -53.7 to -36.8]) compared with onabotulinumtoxinA (-25.1 [95% CI, -34.1 to -16.1]) (P < .001); however, no significant difference was seen between groups in UDI irritative score (onabotulinumtoxinA: -32.9 [95% CI, -40.3 to -25.6] vs sling: -27.4 [95% CI, -34.6 to -20.3]; P = .27). In the onabotulinumtoxinA group, 12.7% and 28.2% received a second injection by 6 and 12 months, respectively. By 12 months, 30.3% in the sling group received onabotulinumtoxinA, and 15.5% in the onabotulinumtoxinA group received a sling. Overall, adverse events were not different between groups. CONCLUSIONS AND RELEVANCE: There was no observed difference in UDI total score improvement at 6 months between the onabotulinumtoxinA and midurethral sling groups in females with moderate to severe mixed urinary incontinence who previously did not respond to conservative treatments. These findings may help inform treatment decisions based on patient preference in partnership with clinician recommendations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04171531.
引用
- Harvie HS, Menefee SA, Richter HE, et al. Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial. JAMA. 2025. PMID: 40323617. doi:10.1001/jama.2025.4682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。